| Dr Rania Mary Shammas, MD | |
|
2625 W Alameda Ave Ste 322, Burbank, CA 91505-4822 | |
| (818) 843-9020 | |
| Not Available |
| Full Name | Dr Rania Mary Shammas |
|---|---|
| Gender | Female |
| Speciality | Rheumatology |
| Experience | 19 Years |
| Location | 2625 W Alameda Ave Ste 322, Burbank, California |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1194959338 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RR0500X | Internal Medicine - Rheumatology | A104236 (California) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Ronald Reagan Ucla Medical Center | Los angeles, CA | Hospital |
| Providence Saint Joseph Medical Ctr | Burbank, CA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| The Regents Of The University Of California | 1355248584 | 1177 |
News Archive
Ligon Discovery announced today that it has entered into a collaboration agreement with Lycera Corporation to apply its Small Molecule Microarray (SMM) screening technology to identify first-in-class drug candidates for immune disorders. Ligon will apply its SMM technology to screen protein targets identified by Lycera as critical to the development of certain immune disorders. Financial terms were not disclosed.
People with type 2 diabetes who intensively controlled their blood sugar level during the landmark Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial Eye Study were found to have cut their risk of diabetic retinopathy in half in a follow-up analysis conducted four years after stopping intensive therapy.
Mayo Clinic researchers have discovered an inherited structural mechanism that can make drugs for some diseases toxic for some patients.
"Adult women who had their first menstruation at the age of 10 or earlier have significantly lower lung capacity than women who had their first period at 13", Ferenc Macsali, lead author of the study and a researcher at the Haukeland Hospital in Bergen (Norway), tells SINC.
Treatment with dexpramipexole - a novel drug believed to prevent dysfunction of mitochondria, the subcellular structures that provide most of a cell's energy - appears to slow symptom progression in the neurodegenerative disease amyotrophic lateral sclerosis (ALS). Promising results of a phase 2 trial of dexpramipexole are receiving advance online publication in Nature Medicine.
› Verified 7 days ago
| Entity Name | Alameda Health System |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1740332931 PECOS PAC ID: 3779494521 Enrollment ID: O20031110000764 |
News Archive
Ligon Discovery announced today that it has entered into a collaboration agreement with Lycera Corporation to apply its Small Molecule Microarray (SMM) screening technology to identify first-in-class drug candidates for immune disorders. Ligon will apply its SMM technology to screen protein targets identified by Lycera as critical to the development of certain immune disorders. Financial terms were not disclosed.
People with type 2 diabetes who intensively controlled their blood sugar level during the landmark Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial Eye Study were found to have cut their risk of diabetic retinopathy in half in a follow-up analysis conducted four years after stopping intensive therapy.
Mayo Clinic researchers have discovered an inherited structural mechanism that can make drugs for some diseases toxic for some patients.
"Adult women who had their first menstruation at the age of 10 or earlier have significantly lower lung capacity than women who had their first period at 13", Ferenc Macsali, lead author of the study and a researcher at the Haukeland Hospital in Bergen (Norway), tells SINC.
Treatment with dexpramipexole - a novel drug believed to prevent dysfunction of mitochondria, the subcellular structures that provide most of a cell's energy - appears to slow symptom progression in the neurodegenerative disease amyotrophic lateral sclerosis (ALS). Promising results of a phase 2 trial of dexpramipexole are receiving advance online publication in Nature Medicine.
› Verified 7 days ago
| Entity Name | The Regents Of The University Of California |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1235107566 PECOS PAC ID: 1355248584 Enrollment ID: O20031223000439 |
News Archive
Ligon Discovery announced today that it has entered into a collaboration agreement with Lycera Corporation to apply its Small Molecule Microarray (SMM) screening technology to identify first-in-class drug candidates for immune disorders. Ligon will apply its SMM technology to screen protein targets identified by Lycera as critical to the development of certain immune disorders. Financial terms were not disclosed.
People with type 2 diabetes who intensively controlled their blood sugar level during the landmark Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial Eye Study were found to have cut their risk of diabetic retinopathy in half in a follow-up analysis conducted four years after stopping intensive therapy.
Mayo Clinic researchers have discovered an inherited structural mechanism that can make drugs for some diseases toxic for some patients.
"Adult women who had their first menstruation at the age of 10 or earlier have significantly lower lung capacity than women who had their first period at 13", Ferenc Macsali, lead author of the study and a researcher at the Haukeland Hospital in Bergen (Norway), tells SINC.
Treatment with dexpramipexole - a novel drug believed to prevent dysfunction of mitochondria, the subcellular structures that provide most of a cell's energy - appears to slow symptom progression in the neurodegenerative disease amyotrophic lateral sclerosis (ALS). Promising results of a phase 2 trial of dexpramipexole are receiving advance online publication in Nature Medicine.
› Verified 7 days ago
| Entity Name | Amicus Arthritis And Osteoporosis Center Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1578946109 PECOS PAC ID: 5597073718 Enrollment ID: O20151007001782 |
News Archive
Ligon Discovery announced today that it has entered into a collaboration agreement with Lycera Corporation to apply its Small Molecule Microarray (SMM) screening technology to identify first-in-class drug candidates for immune disorders. Ligon will apply its SMM technology to screen protein targets identified by Lycera as critical to the development of certain immune disorders. Financial terms were not disclosed.
People with type 2 diabetes who intensively controlled their blood sugar level during the landmark Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial Eye Study were found to have cut their risk of diabetic retinopathy in half in a follow-up analysis conducted four years after stopping intensive therapy.
Mayo Clinic researchers have discovered an inherited structural mechanism that can make drugs for some diseases toxic for some patients.
"Adult women who had their first menstruation at the age of 10 or earlier have significantly lower lung capacity than women who had their first period at 13", Ferenc Macsali, lead author of the study and a researcher at the Haukeland Hospital in Bergen (Norway), tells SINC.
Treatment with dexpramipexole - a novel drug believed to prevent dysfunction of mitochondria, the subcellular structures that provide most of a cell's energy - appears to slow symptom progression in the neurodegenerative disease amyotrophic lateral sclerosis (ALS). Promising results of a phase 2 trial of dexpramipexole are receiving advance online publication in Nature Medicine.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Rania Mary Shammas, MD 2625 W Alameda Ave Ste 322, Burbank, CA 91505-4822 Ph: (818) 843-9020 | Dr Rania Mary Shammas, MD 2625 W Alameda Ave Ste 322, Burbank, CA 91505-4822 Ph: (818) 843-9020 |
News Archive
Ligon Discovery announced today that it has entered into a collaboration agreement with Lycera Corporation to apply its Small Molecule Microarray (SMM) screening technology to identify first-in-class drug candidates for immune disorders. Ligon will apply its SMM technology to screen protein targets identified by Lycera as critical to the development of certain immune disorders. Financial terms were not disclosed.
People with type 2 diabetes who intensively controlled their blood sugar level during the landmark Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial Eye Study were found to have cut their risk of diabetic retinopathy in half in a follow-up analysis conducted four years after stopping intensive therapy.
Mayo Clinic researchers have discovered an inherited structural mechanism that can make drugs for some diseases toxic for some patients.
"Adult women who had their first menstruation at the age of 10 or earlier have significantly lower lung capacity than women who had their first period at 13", Ferenc Macsali, lead author of the study and a researcher at the Haukeland Hospital in Bergen (Norway), tells SINC.
Treatment with dexpramipexole - a novel drug believed to prevent dysfunction of mitochondria, the subcellular structures that provide most of a cell's energy - appears to slow symptom progression in the neurodegenerative disease amyotrophic lateral sclerosis (ALS). Promising results of a phase 2 trial of dexpramipexole are receiving advance online publication in Nature Medicine.
› Verified 7 days ago
Boris Arbit, M.D. Rheumatology Medicare: Accepting Medicare Assignments Practice Location: 2625 W Alameda Ave Ste 322, Burbank, CA 91505 Phone: 818-843-9015 Fax: 818-843-9016 | |
Dr. Daniel Kwan Dea, M.D. Rheumatology Medicare: Accepting Medicare Assignments Practice Location: 2701 W Alameda Ave, Suite 601, Burbank, CA 91505 Phone: 818-846-2766 Fax: 818-556-4170 | |
Dr. Abigail Maller, M.D. Rheumatology Medicare: Accepting Medicare Assignments Practice Location: 2625 W Alameda Ave Ste 322, Burbank, CA 91505 Phone: 818-843-9015 Fax: 818-843-9016 | |
Dr. Mark A Gerard, MD Rheumatology Medicare: Accepting Medicare Assignments Practice Location: 201 S Buena Vista St, Suite # 250, Burbank, CA 91505 Phone: 818-562-3200 Fax: 818-562-3205 | |
Jamileh Hanna, MD Rheumatology Medicare: Medicare Enrolled Practice Location: 2550 N Hollywood Way Ste 100, Burbank, CA 91505 Phone: 818-524-3730 Fax: 818-847-8675 | |
Dr. Cecelia Theresa Madrid, M.D. Rheumatology Medicare: Medicare Enrolled Practice Location: 2701 W Alameda Ave Ste 500, Burbank, CA 91505 Phone: 818-567-6550 Fax: 818-558-4379 | |
Grace I Wong, M.D. Rheumatology Medicare: Accepting Medicare Assignments Practice Location: 3808 W Riverside Dr Ste 201, Burbank, CA 91505 Phone: 818-563-1449 Fax: 818-563-1049 |